Skip NavigationSkip to Content

Myeloid Wnt ligands are required for normal development of dermal lymphatic vasculature

  1. Author:
    Muley, Ajit
    Odaka, Yoshi
    Lewkowich, Ian P
    Vemaraju, Shruti
    Yamaguchi, Terry
    Shawber, Carrie
    Dickie, Belinda H
    Lang, Richard A [ORCID]
  2. Author Address

    Department of OB-GYN, Columbia University Medical Center, Columbia University, New York City, New York, United States of America., Visual Systems Group, Division of Pediatric Ophthalmology, Cincinnati Children 39;s Hospital Medical Center, Cincinnati, Ohio, United States of America., Division of Immunobiology, Cincinnati Children 39;s Hospital Medical Center, Cincinnati, Ohio, United States of America., Cancer and Developmental Biology Laboratory, National Cancer Institute, Frederick, Maryland, United States of America., Department of Surgery, Boston Children 39;s Hospital, Boston, Massachusetts, United States of America., Center for Chronobiology, Cincinnati Children 39;s Hospital Medical Center, Cincinnati, Ohio, United States of America., Abrahamson Pediatric Eye Institute, Cincinnati Children 39;s Hospital Medical Center, Cincinnati, Ohio, United States of America., Division of Developmental Biology, Cincinnati Children 39;s Hospital Medical Center, Cincinnati, Ohio, United States of America., Department of Ophthalmology, College of Medicine, University of Cincinnati, Cincinnati, Ohio, United States of America.,
    1. Year: 2017
    2. Date: Aug 28
  1. Journal: PLoS One
    1. 12
    2. 8
    3. Pages: e0181549
  2. Type of Article: Article
  3. Article Number: e0181549
  4. ISSN: 1932-6203
  1. Abstract:

    Resident tissue myeloid cells play a role in many aspects of physiology including development of the vascular systems. In the blood vasculature, myeloid cells use VEGFC to promote angiogenesis and can use Wnt ligands to control vascular branching and to promote vascular regression. Here we show that myeloid cells also regulate development of the dermal lymphatic vasculature using Wnt ligands. Using myeloid-specific deletion of the WNT transporter Wntless we show that myeloid Wnt ligands are active at two distinct stages of development of the dermal lymphatics. As lymphatic progenitors are emigrating from the cardinal vein and intersomitic vessels, myeloid Wnt ligands regulate both their numbers and migration distance. Later in lymphatic development, myeloid Wnt ligands regulate proliferation of lymphatic endothelial cells (LEC) and thus control lymphatic vessel caliber. Myeloid-specific deletion of WNT co-receptor Lrp5 or Wnt5a gain-of-function also produce elevated caliber in dermal lymphatic capillaries. These data thus suggest that myeloid cells produce Wnt ligands to regulate lymphatic development and use Wnt pathway co-receptors to regulate the balance of Wnt ligand activity during the macrophage-LEC interaction.

    See More

External Sources

  1. DOI: 10.1371/journal.pone.0181549
  2. PMID: 28846685
  3. WOS: 000408438600006

Library Notes

  1. Open Access Publication
  2. Fiscal Year: FY2016-2017
  3. Group/Lab/Department: Cancer and Developmental Biology Laboratory, Co-Chiefs = Alan O. Perantoni (NCI) and Ira O. Daar (NCI)
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel